Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819390 | 0.91 | KDM4E (0.64) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL31129249 | 0.86 | KMT2A (0.67) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL3761569 | 0.86 | KMT2A (0.68) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL10404298 | 0.86 | KMT2A (0.67) | KMT2AMEN1MAPTKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL38658753 | 0.84 | KMT2A (0.66) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL22773569 | 0.84 | KMT2A (0.65) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL6819399 | 0.84 | KMT2A (0.50) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL14339871 | 0.84 | MEN1 (0.67) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL12049704 | 0.83 | KMT2A (0.68) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL13036489 | 0.83 | KMT2A (0.60) | KMT2AMEN1MAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020248972-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-12-17 | — | — | WO | claimed |
| WO-2026107381-A1 | DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3347097-B1 | SUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE KINASES JAK, FLT3 AND AURORA | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020248972-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-12-17 | — | — | WO | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| WO-2008008732-A2 | SUBSTITUTED AMINOPYRIDINES AS FLUORESCENT REPORTERS FOR AMIDE HYDROLASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-17 | — | — | WO | disclosed |
| CN-100338042-C | Triazole derivatives as cyclooxygenase (COX) inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-09-19 | — | — | CN | disclosed |
| CN-1612865-A | Triazole derivatives as cyclooxygenase (COX) inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-04 | — | — | CN | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | KMT2A 461/4885MEN1 2981/4885MAPT 1988/4885 |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | KMT2A 2727/4885MEN1 4186/4885MAPT 3611/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KMT2A 461/4885MEN1 2981/4885MAPT 1988/4885 |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KMT2A 3246/4885MEN1 4396/4885MAPT 899/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KMT2A 3246/4885MEN1 4396/4885MAPT 899/4885 |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | KMT2A 1707/4885MEN1 3058/4885MAPT 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.